Allogeneic Recognition and Immune Tolerance in Lung Transplantation

Lung and Heart–Lung Transplantation

Volumn , Issue , 2006, Pages 47-60

  Meyer, Keith C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47249165170     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019285-7     Document Type: Chapter

References (80)

1. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20:77–82.
2. Roopenian D, Choi EY, Brown A. The immunogenomics of minor histocompatibility antigens. Immunol Rev 2002; 190:86–94.
3. Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 1998; 19:69–74.
4. Malarkannan S, Pooler LM. Minor histocompatibility antigens: molecular barriers for sucessful tissue transplantation. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/ Plenum, 2004:71–105.
5. Bingaman AW, Ha J, Waitze SY, et al. Vigorous allograft rejection in the absence of danger. J Immunol 2000; 164:3065–3071.
6. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106:259–262.
7. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ‘‘ignorance’’ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6:686–688.
8. Chalermskulrat W, Neuringer IP, Schmitz JL, et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003; 123:1825–1831.
9. Fangmann J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992; 175:1521–1529.
10. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990; 11:83–88.
11. Frasca L, Amendola A, Hornick P, et al. Role of donor and recipient antigenpresenting cells in priming and maintaining T cells with indirect allospecificity. Transplantation 1998; 66:1238–1243.
12. Burlingham WJ, Torrealba J. Immunologic tolerance as taught by allografts. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/Plenum, 2004:139–158.
13. Kishimoto K, Sandner S, Imitola J, et al. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest 2002; 109:1471–1479.
14. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8(þ) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3:844–851.
15. Meyer KC. The role of neutrophils in transplantation. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/Plenum, 2004:493–507.
16. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2:662–665.
17. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735–739.
18. Koka P, Cecka JM. Sensitization and crossmatching in renal transplantation. Clin Transpl 1989; 379–390.
19. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1–15.
20. Baldwin WM III, Ota H, Wasowska BA, et al. Complement system in allorecognition and rejection of organ transplants. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/ Plenum, 2004:139–158.
21. Magro CM, Klinger DM, Adams PW, et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003; 3:1264–1272.
22. Magro CM, Ross P Jr, Kelsey M, Waldman WJ, Pope-Harman A. Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant 2003; 3:1155–1166.
23. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166:440–444.
24. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25:119–140.
25. Field EH, Wood KJ. Regulatory T cells: professional supressor cells. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/Plenum, 2004:313–327.
26. Kruisbeek AM, Amsen D. Mechanisms underlying T-cell tolerance. Curr Opin Immunol 1996; 8:233–244.
27. Claas FHJ. HLA immunogenetics and transplantation. In: Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York: Kluwer Academic/Plenum, 2004:45–52.
28. Maruya E, Takemoto S, Terasaki PI. HLA matching: identification of permissible HLA mismatches. Clin Transpl 1993: 511–520.
29. Hendriks GF, D’Amaro J, Persijn GG, et al. Excellent outcome after transplantation of renal allografts from HLA-DRw6-positive donors even in HLA-DR mismatches. Lancet 1983; 2:187–189.
30. Smits JM, Vanhaecke J, Haverich A, et al. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997–1999. Clin Transpl 2003; 89–100.
31. Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19:473–479.
32. van den Berg JW, Hepkema BG, Geertsma A, et al. Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches. Transplantation 2001; 71:368–373.
33. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol 2004; 13:63–71.
34. Lu KC, Jaramillo A, Mendeloff EN, et al. Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22:35–43.
35. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74:799–804.
36. Wrenshall L. Role of the microenvironment in immune responses to transplantation. Springer Semin Immunopathol 2003; 25:199–213.
37. Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003; 3:794–803.
38. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1129–L1139.
39. Wilkes DS, Heidler KM, Bowen LK, et al. Allogeneic bronchoalveolar lavage cells induce the histology of acute lung allograft rejection, and deposition of IgG2a in recipient murine lungs. J Immunol 1995; 155:2775–2783.
40. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169:1542–1549.
41. Yasufuku K, Heidler KM, O’Donnell PW, et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001; 25:26–34.
42. O’Connell PJ, Mba-Jonas A, Leverson GE, et al. Stable lung allograft outcome correlates with the presence of intragraft donor-derived leukocytes. Transplantation 1998; 66:1167–1174.
43. Pham SM, Rao AS, Zeevi A, et al. Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg 2000; 69:345–350.
44. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184:387–396.
45. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151–1164.
46. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4þCD25þ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160: 1212–1218.
47. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(þ)CD25(þ) T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303–1310.
48. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(þ)CD25(þ) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285–1294.
49. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(þ)CD25(þ) and CD4(þ)CD25(_) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168:5558–5565.
50. Gaur A, Ruberti G, Haspel R, Mayer JP, Fathman CG. Requirement for CD8þ cells in T cell receptor peptide-induced clonal unresponsiveness. Science 1993; 259:91–94.
51. Koh DR, Fung-Leung WP, Ho A, Gray D, Acha-Orbea H, Mak TW. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8_/_ mice. Science 1992; 256:1210–1213.
52. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virusspecific regulatory CD8(þ) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113:963–972.
53. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3:253–257.
54. Piccirillo CA, Shevach EM. Naturally-occurring CD4þCD25þ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16:81–88.
55. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002; 110:693–702.
56. Waldmann H, Cobbold S. Regulating the immune response to transplants: a role for CD4þ regulatory cells? Immunity 2001; 14:399–406.
57. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(þ) regulatory T cell function. J Exp Med 2002; 196:851–857.
58. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995; 268:1472–1476.
59. Bushell A, Niimi M, Morris PJ, Wood KJ. Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J Immunol 1999; 162:1359–1366.
60. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166:3789–3796.
61. Gorelik L, Flavell RA. Abrogation of TGF beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171–181.
62. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195:1641–1646.
63. van Maurik A, Herber M, Wood KJ, Jones ND. Cutting edge: CD4þCD25þ alloantigen-specific immunoregulatory cells that can prevent CD8þ T cellmediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 2002; 169:5401–5404.
64. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46–53.
65. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(þ)CD25(þ) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194:629–644.
66. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601–609.
67. Yasufuku K, Heidler KM, Woods KA, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73:500–505.
68. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725–731.
69. Goudy KS, Burkhardt BR, Wasserfall C, et al. Systemic overexpression of IL-10 induces CD4þCD25þ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171:2270–2278.
70. Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003; 75:8S–12S.
71. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503–513.
72. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIBdeficient mice results from strain-specific epistasis. Immunity 2000; 13:277–285.
73. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307:590–593.
74. Meloni F, Vitulo P, Bianco AM, et al. Regulatory CD4þCD25þ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004; 77:762–766.
75. Mizobuchi T, Yasufuku K, Zheng Y, et al. Differential expression of Smad7 transcripts identifies the CD4þCD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171: 1140–1147.
76. Zheng HX, Burckart GJ, McCurry K, et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 2004; 23:541–546.
77. Thornton AM, Shevach EM. CD4þCD25þ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287–296.
78. Huss R. In vitro determination of self-reactivity in the early postcyclosporine period. Transpl Immunol 1993; 1:228–234.
79. Sakaguchi S, Sakaguchi N. Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A-treated mice causes organ-specific autoimmune disease in athymic nude mice. J Exp Med 1988; 167:1479–1485.
80. Sakaguchi S, Sakaguchi N. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J Immunol 1989; 142:471–480.